Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 20978761

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Cancer Chemother Pharmacol
Publication date
2011 Aug
First author
Yuan Y

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Yuan Y
      type
      Author
    2. name
      Cohen DJ
      type
      Author
    3. name
      Love E
      type
      Author
    4. name
      Yaw M
      type
      Author
    5. name
      Levinson B
      type
      Author
    6. name
      Nicol SJ
      type
      Author
    7. name
      Hochster HS
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Yuan Y
      type
      Author
    2. name
      Cohen DJ
      type
      Author
    3. name
      Love E
      type
      Author
    4. name
      Yaw M
      type
      Author
    5. name
      Levinson B
      type
      Author
    6. name
      Nicol SJ
      type
      Author
    7. name
      Hochster HS
      type
      Author
    bibliography ids
    1. nci-bib-f304971a68e1487f0cb39f6e
    book metadata
    content sha256
    5a523eff0d27a4c2bcd217d3e4d2c2d14072bd8e2b844e14cf1e64aab95eb417
    document type
    citation
    dois
    1. 10.1007/s00280-010-1493-8
    electronic publication date
    display
    2010 Oct 27
    precision
    day
    year
    2010
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:20978761
    immutable id
    pubmed:20978761@5a523eff0d27a4c2bcd217d3e4d2c2d14072bd8e2b844e14cf1e64aab95eb417
    journal
    abbreviation
    Cancer Chemother Pharmacol
    issn electronic
    1432-0843
    issn print
    0344-5704
    issue
    2
    name
    Cancer chemotherapy and pharmacology
    nlm unique id
    7806519
    pages
    371-8
    volume
    68
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      20978761
      provenance
      batch id
      10a38257e12e9ed1867a
      provider
      NCBI PubMed ESummary
      record sha256
      e7c9aec9e6a7ece18f05b1644eef0c98e1805a124c506e99496c232ac470d711
      response sha256
      84c4808ca38b35d999cfdf809eb088835175ab38d71586c626096d677096bbcc
      retrieved at
      2026-09-09T23:46:35.793530+00:00
      publication date
      display
      2011 Aug
      precision
      month
      year
      2011
      publication types
      1. Clinical Trial, Phase I
      2. Journal Article
      3. Research Support, N.I.H., Extramural
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/20978761/
      title
      Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

      Preserved source evidence · Not medical advice